DataMeds AI, Inc. MEDS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, DataMeds AI, Inc. reported revenue across 3 products and services; the largest, Product, was $21.9M, 93.7% of the filed sum (+23.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$21.9M93.7%+23.8% yoy
- Pharmacy Retail Sales$866K3.7%+145.7% yoy
- Third Party Logistics Services$603K2.6%+463.9% yoy
Members sum to the consolidated $23.3M for this period.
- Pharmacy Retail Sales$1.13M72.7%+889.2% yoy
- Product$226K14.5%-97.9% yoy
- Third Party Logistics Services$199K12.8%+147.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.